You are here
Monday, April 14, 2008
Launching a Global Alliance for Pharmacogenomics
U.S. and Japanese Scientists Partner to Study Genetic Factors that Influence the Safety and Effectiveness of Medicines
Leaders at the National Institutes of Health and the Center for Genomic Medicine in Japan have signed a letter of intent creating a Global Alliance for Pharmacogenomics. The effort aims to identify genetic factors that contribute to individual responses to medicines, including rare and dangerous side effects. The results of such work will eventually help doctors optimize the safety and effectiveness of drugs for each patient.
U.S. scientists joining the alliance are members of the NIH Pharmacogenetics Research Network, a consortium of research groups that study how genetic factors influence the way drugs work in and are handled by the body.
Japanese scientists in the alliance represent the newly created Center for Genomic Medicine, a component of the RIKEN Yokohama Institute that conducts high-throughput analyses of human genes involved in diseases and drug responses.
Signers of the agreement include the directors of three of the National Institutes of Health: Jeremy M. Berg, Ph.D., director of the National Institute of General Medical Sciences; Elizabeth G. Nabel, M.D., director of the National Heart, Lung, and Blood Institute; and John E. Niederhuber, M.D., director of the National Cancer Institute.
"By bringing together our resources, we will advance the understanding of how changes in DNA affect our responses to medicines. Thus we can begin to realize the promise of personalized medicine," said Yusuke Nakamura, M.D., Ph.D., director of the Center for Genomic Medicine at RIKEN.
"We expect this international agreement to speed scientific discovery and the translation of results into improved treatments for cancer, heart disease and other serious conditions," said NIH Director Elias A. Zerhouni, M.D. "Ultimately, physicians worldwide will be able to tailor the treatment of each patient — one of the great frontiers of health care today."
Initial projects will focus on:
- Understanding genetic factors that influence the effectiveness of breast cancer treatments (aromatase inhibitors)
- Determining the optimal length of treatment for two drugs used to treat early stage breast cancer (cyclophosphamide and either doxorubicin or paclitaxel)
- Discovering new genetic factors linked to serious side effects from certain pancreatic cancer drugs (gemcitabine and bevacizumab)
- Exploring how genes contribute to drug-induced long QT syndrome, an irregular heart rhythm that can cause sudden cardiac arrest
- Working with the International Warfarin Consortium to tailor initial doses of the anti-clotting drug warfarin based on the genetic profiles of patients
A steering committee will manage the alliance and will meet twice a year to discuss progress, future directions, intellectual property issues, the approval of additional members and communication with the public. Alliance members will share their data and their research results with the scientific community.
The letter of intent is available at http://www.nigms.nih.gov/Initiatives/PGRN/GAP/. This site also includes acknowledgements of the research centers that provided DNA samples essential to perform the work.
To interview signers of the letter of intent or scientists involved in the Global Alliance for Pharmacogenomics, please contact the NIGMS Office of Communications and Public Liaison at 301-496-7301 or firstname.lastname@example.org.
The RIKEN Center for Genomic Medicine (http://www.src.riken.jp/english), formerly named the SNP Research Center, is known as a major contributor to the International HapMap project. The Center aims to advance the practice of personalized medicine through conducting whole-genome association studies to find genetic variations associated with disease susceptibility and drug responses.
The National Institute of General Medical Sciences (http://www.nigms.nih.gov) supports basic biomedical research that is the foundation for advances in disease diagnosis, treatment, and prevention.
The National Heart, Lung, and Blood Institute (http://www.nhlbi.nih.gov) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics.
The National Cancer Institute (http://www.cancer.gov/) conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®